Opis działalności
Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Patrick Amstutz |
| Zarząd |
| Alexander Zürcher, Philippe Legenne, M.D., MBA, Dr. Michael Tobias Stumpp, Renate Gloggner, Anne Goubier, D.V.M., Ph.D., Robert Hendriks, Dr. Julia Hepp, Michael Pitzner, Seth Lewis, Dr. Daniel Steiner, Baris Arican, MBA |
| Rada nadzorcza |
| William Burns, Dr. Patrick Amstutz, Dr. Agnete Fredriksen, Dominik Höchli, M.D., Steven H. Holtzman, Sandip Kapadia, Dr. Vito L. Palombella, Dr. Michal Vasconelles |
Dane firmy
| Nazwa: |
Molecular Partners AG |
| Adres: |
Wagistrasse 14,CH-8952 Zürich-Schlieren |
| Telefon: |
+41-44-755-77-00 |
| Fax: |
+41-44-755-77-07 |
| E-mail: |
-
|
| Internet: |
www.molecularpartners.com |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
58,15% |
| Data IPO: |
- |
